Search Technologies
Displaying 21 - 30 of 33 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
Repurposed drugs for Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Published Monday, November 24, 2014Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) are viral respiratory diseases caused by novel coronavirus strains (SARS-CoV and MERS-CoV, respectively). Categorized as a select agent in 2012, approximately 9,000 cases of SARS have been reported, with 9.5% mortality rate. To date, there have been 1,917...
Investigator(s): Mathew Frieman, Lisa Hensley, Peter Jahrling
Categories: Therapeutics, Small molecules, Chemicals, Repurpose Drug
Keyword(s): MERS, SARS, Repurposed drugs, antiviral drugs
Docket: MF-2014-090
-
Use of Trehalose for Prevention of Neural Tube Defects
Published Thursday, May 29, 2014The neural tube is a specialized part of the embryo that forms the skull, brain and spinal cord in adults and requires an effective balance between cell death and survival. Disruption of this process causes neural tube defects (NTDs) such as spina bifida, anencephaly, and encephalocele. UMB researchers have discovered Trehalose treatment...
Investigator(s): Peixin Yang, E. Albert Reece
Categories: Therapeutics, Small molecules
Keyword(s): Trehalose, diabetes
Docket: PY-2012-118
-
Use of Novel Sulfonamides to Inhibit the Growth of Prostate Cancer Cells and Tumors
Published Thursday, May 29, 2014According to the American Cancer Society, prostate cancer (PCA) is the most common type of cancer found in American men. Currently, the major therapy for PCA in both primary and advanced stages is androgen deprivation. This treatment exerts its effects on target tissue by either blocking androgen synthesis or preventing binding of androgens to...
Investigator(s): Vincent C. O. Njar, Puranik Purushottamachar
Categories: Therapeutics, Small molecules
Keyword(s): prostate cancer, cancer
Docket: VN-2007-026
-
Targeting NAD biosynthesis in bacterial pathogens
Published Thursday, May 29, 2014The increasing incidence of antibiotic-resistant pathogens is a major health crisis, particularly in hospital settings in the developed world. It has been estimated that ~70% of hospital-acquired infections involve multi-antibiotic resistant organisms, resulting in ~90,000 annual deaths at a cost of 4.5ý6.0 billion per year (Burke, 2003)....
Investigator(s): Alexander J MacKerell, Hong Zhang, Andrea L Osterman
Categories: Therapeutics, Small molecules
Keyword(s): biosynthesis, pathogens
Docket: AM-2009-069
-
Small Molecule Inhibitors of BCL6
Published Thursday, May 29, 2014BCL6 is a transcription factor essential for germinal center B-cell development. The BTB domain (also known as the POZ domain) is a common protein-protein interaction motif that is found in over 180 human proteins including BCL6 and has been implicated in many biological processes including central nervous development, oocyte maturation, eye...
Investigator(s): Alexander Donald MacKerell, Jr., Ari M. Melnic, k Gilbert G. Prive
Categories: Therapeutics, Small molecules
Keyword(s): small molecules
Docket: AM-2007-053
-
Small Molecule Inhibitors Of Kynurenine 3-Monooxygenase
Published Thursday, May 29, 2014Kynurenic acid has neuroprotective activities in vivo while the metabolic byproduct of kynurenic acid, quinolinic acid, is neurotoxic. Kynurenine 3-monooxygenase catalyzes the conversion of kynurenine into 3-hydroxykynurenine, a precusor of neurotoxic quinolinic acid. In light the properties of kynurenic acid and quinolinic acid,...
Investigator(s): Robert Schwarcz, Paulo Guidetti
Categories: Therapeutics, Small molecules
Docket: RS-2007-032
-
Novel Opioid Analgesics With Reduced Tolerance
Published Wednesday, May 28, 2014UMB 425 is a novel opioid with bi-functional activity that combines a delta-opioid antagonist and a mu-opioid agonist in a single compound with antinociceptive effects comparable to morphine. With reduced tolerance liabilities, UMB 425 provides a novel therapeutic approach in the treatment of patients who suffer from chronic pain with...
Investigator(s): Andrew Coop, Alexander MacKerell, Rae R. Matsumoto
Categories: Therapeutics, Small molecules
Keyword(s): Opioid, tolerance, analgesic
Docket: AC-2013-055
-
Methods for Regulating Urinary Potassium
Published Wednesday, May 28, 2014Potassium is the most abundant intracellular cation. It is critically important for many physiologic processes, including maintenance of cellular membrane potential, homeostasis of cell volume, and transmission of action potentials in nerve cells. Small changes in the extracellular potassium level can have profound effects on the function of...
Investigator(s): Paul Welling, Liang Feng
Categories: Therapeutics, Small molecules, Biologics
Keyword(s): Urinary Potassium, potassium
Docket: PW-2008-072
-
Inhibitors of S100 Proteins for the Treatment of Cancer and Other Diseases Involving Uncontrolled Cell Growth via an S100-Dependent Pathway
Published Wednesday, May 28, 2014Small molecules have been identified, using rational drug design, that bind to a site on S100 proteins, rendering S100 incapable of inactivating p53 tumor suppressor protein. Inhibitors of S100 thus restore tumor suppressor activity of the p53 protein by inhibiting the S100-p53 interaction. Inhibitors are specific to different members of the...
Investigator(s): David Weber, Joseph Markowitz, France Carrier
Categories: Diagnostics, Therapeutics, Small molecules
Keyword(s): tumor, cancer, S100 proteins, research tools
Docket: DW-2002-041
-
Inhibitors of Extracellular Signal-Regulated Kinase (ERK) regulated signaling pathways
Published Wednesday, May 28, 2014This technology is a set of novel ATP-independent, extracellular signal-regulated kinase (ERK) inhibitors that have the potenital to provide specific targeting compared to existing ERK1/2 inhibitors. The lead ATP-independent ERK inhibitor candidates, interact with specific ERK substrate...
Investigator(s): Paul Shapiro, Stephen Fletcher, Alex MacKerell
Categories: Therapeutics, Small molecules
Keyword(s): Signal-Regulated Kinase, ERK
Docket: PS-2013-025,PS-2013-054